Shots:

• Janssen acquires rights to Hemera’s HMR59- administered as a one-time- outpatient- IVT inj. to help preserve vision in patients with geographic atrophy
• The acquisition will boost Janssen's eye disease portfolio & strengthens its gene therapy capabilities
• HMR59 is designed to increase the ability of retina cells to make a soluble form of CD59- helping to prevent further damage to the retina and preserve vision. The P-I study of the therapy for patients with geographic atrophy is completed while the P-I study exploring HMR59 in patients with wet-AMD is currently conducting follow-up visits to evaluate the long-term safety

 ­ Ref: PRNewswire | Image: Janssen